Tevogen Bio Inc

Tevogen Bio will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference, focusing on AI in Biopharma and the Economics of Health, featuring industry leaders like David Rhew and Poonam Alaigh.

Tevogen Bio filed a patent for 'Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models' to strengthen its IP portfolio. The company launched Tevogen.AI in Oct 2023 to enhance drug discovery, development, and manufacturing. Key developments include Mittul Mehta's appointment to lead Tevogen.AI, a partnership with Microsoft in May 2024, successful machine learning application for HPV target identification in Nov 2024, and filing of International Application PCT/US2024/060419 on Dec 16, 2024. Tevogen's ExacTcell™ technology aims to create CTL products targeting various viruses, with plans to provide updates at the J.P. Morgan Healthcare Conference in Jan 2025.

The article discusses the importance of enabling JavaScript for optimal app performance.

Tevogen Bio partners with Microsoft to use AI for HPV target identification, advancing TVGN 920 oncology treatment with ExacTcell™ technology, targeting 5.5 million women annually affected by HPV.

Tevogen Bio, a clinical-stage immunotherapy biotech, provides guidance on its first ExacTcell™ technology product, TVGN 489, designed to treat SARS-CoV-2 infections in immunocompromised oncology patients and post-acute sequelae of SARS-CoV-2 (PASC). The company plans market entry by end of 2026, with CEO Ryan Saadi emphasizing rapid and cost-effective development of TVGN 489. Tevogen's pipeline includes treatments for various cancers, multiple sclerosis, and Long COVID, aiming to address unmet needs through accessible, off-the-shelf T cell therapeutics.

Tevogen Bio, a clinical-stage immunotherapy biotech, partners with Microsoft for Startups to accelerate AI-driven drug development, aiming to lower costs and expedite delivery of therapies for infectious diseases and cancers.

Tevogen Bio, a clinical-stage immunotherapy biotech, develops off-the-shelf T cell therapeutics for infectious diseases and cancers. Founded in 2020, it launched ExacTcell™ technology, received 3 US patents, and reported positive clinical trial data. Officers hold 79% of shares, emphasizing commitment to accessible therapeutics. Tevogen aims to address unmet needs in large patient populations through innovative business models and advanced science.

Tevogen Bio Inc. and CEO Dr. Ryan Saadi honored by Warren Township for Nobel Prize nomination, recognizing their business model addressing health inequality through life-saving medical innovations.

HMP Partners and The Patel Family LLP congratulate Tevogen Bio and CEO Dr. Ryan Saadi for their Nobel Prize nomination, recognizing their innovative business model to alleviate health inequality through life-saving medical innovations. Warren Township, NJ, issued a proclamation honoring their achievements.